Aurobindo registers net profit of Rs 92 cr in Q3

Aurobindo Pharma posted consolidated net profit of Rs 91.81 crore for the third quarter ended December 31, 2012, on the back of robust sales across domestic and international markets

aurobindo-edited

The Hyderabad-based firm, Aurobindo Pharma has reported consolidated net profit of Rs 91.81 crore during the third quarter ended December 2012 on account of lower foreign exchange loss, as against a net loss of Rs 28.54 crore in the corresponding period of last year. The company management declared interim dividend of 100 percent.

Performance Highlights:

  • Aurobindo's foreign exchange loss declined to Rs 73.36 crore from Rs 144.50 crore in the last period.
  • The EBDITA went up sharply to Rs 264.74 crore from Rs 196.39 crore with higher net sales.
  • Its consolidated net sales increased by 22.8 percent to Rs 1,552 crore from Rs 1,264 crore.
  • The company's formulation sales increased by 22.5 percent to Rs 911.8 crore from Rs 744.3 crore and APIs sales by 21.7 percent to Rs 660.2 crore from Rs 542.7 crore.
  • Its sales in USA improved by 58 percent to Rs 513.4 crore from Rs 325.2 crore in the similar period of last year.

Mr N Govindarajan, managing director, Aurobindo Pharma, said, "We continue to see traction on our performance both in sales and earnings on year-on-year basis on account of improved business mix in formulations from new product approvals and launches in the US market. During the quarter, US FDA cleared Unit-4 (general liquid injectable) after their first inspection and Unit-12 (SSP oral and injectable) on re-inspection and started approving products from these facilities. These will pave the way for consolidating injectable formulations business."

Leave a Reply Sign in

Notify me of follow-up comments via e-mail address

Post Comment

Survey Box

GST

GST: Boon or Bane for Healthcare?

Send this article by email

X